US EditionTargeting 17β-HSD13: Emerging Patent Landscape in Fibrosis and NASH
Summary by Drug Hunter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Targeting 17β-HSD13: Emerging Patent Landscape in Fibrosis and NASH
17β-HSD13 is a member of a 15-enzyme family involved in the metabolism of steroid hormones, fatty acids, cholesterol, and bile acids. It is a promising target for NAFLD and NASH, supported by GWAS data showing that loss-of-function variants reduce liver enzyme levels and disease risk. Clinical validation came from Arrowhead’s ARO-HSD, an siRNA that lowered serum ALT. While the full function of 17β-HSD13 remains unclear, it acts on lipid substrat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium